Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APOBEC3G | Q9HC16 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CETP | P11597 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4441004 | 0.83 | CHRM2 (0.49) | APOBEC3GMEN1KMT2AMAPTPOLB | |
| SCHEMBL7461135 | 0.80 | TDP1 (0.38) | MEN1KMT2ALMNASMN1; SMN2 | |
| SCHEMBL14691235 | 0.79 | POLB (0.55) | MEN1KMT2AMAPTNPSR1POLB | |
| SCHEMBL4436796 | 0.79 | HPGD (0.36) | APOBEC3GKMT2AMAPTNPSR1POLB | |
| SCHEMBL4599233 | 0.78 | MAP2K7 (0.33) | APOBEC3GMEN1KMT2ACETPCHRM2 | |
| SCHEMBL5467662 | 0.77 | APOBEC3G (0.52) | APOBEC3GMEN1KMT2AMAPTNPSR1 | |
| SCHEMBL2306573 | 0.74 | SLC6A4 (0.58) | MEN1KMT2ANPSR1LMNASMN1; SMN2 | |
| SCHEMBL30035899 | 0.73 | APOBEC3G (0.58) | APOBEC3GMEN1KMT2AMAPTNPSR1 | |
| SCHEMBL775852 | 0.73 | APOBEC3G (0.58) | APOBEC3GMEN1KMT2AMAPTNPSR1 | |
| SCHEMBL6446917 | 0.71 | GABRA1 (0.42) | MAPTNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12383518-B2 | Disulfide-masked pro-chelator compositions and methods of use | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2025-08-12 | — | — | US | disclosed |
| US-20220175705-A1 | DISULFIDE-MASKED PRO-CHELATOR COMPOSITIONS AND METHODS OF USE | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA | 2022-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220175705-A1 | DISULFIDE-MASKED PRO-CHELATOR COMPOSITIONS AND METHODS OF USE | ORAI1, SLC40A1, P4HB | APOBEC3G 4518/4885MEN1 1252/4885KMT2A 1866/4885 |
| US-12383518-B2 | Disulfide-masked pro-chelator compositions and methods of use | ORAI1, SLC40A1, P4HB | APOBEC3G 4518/4885MEN1 1252/4885KMT2A 1866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.